File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Spontaneous hepatitis B e-antigen seroconversion without subsequent antiviral therapy is associated with higher rates of hepatitis B surface antigen seroclearance

TitleSpontaneous hepatitis B e-antigen seroconversion without subsequent antiviral therapy is associated with higher rates of hepatitis B surface antigen seroclearance
Authors
Fung, JWong, DSeto, WLai, CYuen, M
KeywordsMedical sciences
Gastroenterology
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD: The Liver Meeting 2013), Washington, DC., 1-5 November 2013. In Hepatology, 2013, v. 58 n. S1, p. 634A, abstract no. 898 How to Cite?
DOI: http://dx.doi.org/10.1002/hep.26727
AbstractBACKGROUND: In chronic hepatitis B (CHB), the implications of hepatitis B e-antigen (HBeAg) seroconversion on subsequent hepatitis B surface antigen (HBsAg) seroclearance has not been documented. METHODS: The Chronic Hepatitis B E-Seroconversion Study (C.H.E.S.S.) cohort follows up a large population of CHB patients with documented HBeAg seroclearance. Patients are followed-up at 3-6 monthly intervals with routine liver biochemistry and viral serological tests. Results: A total of 803 patients with documented HBeAg seroconversion were included, with a median HBeAg seroconversion age of 34 years. The median follow-up length was 123 months after HBeAg seroclearance, with a total of 9250 patient-years. Of these, 502 (62.5%) were male. The cumulative rate of ...
DescriptionPoster - HBV Natural History and Outcomes: abstract no. 898
This journal suppl. entitled: Special Issue: The 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013
Persistent Identifierhttp://hdl.handle.net/10722/198625
ISSN
0270-9139
2021 Impact Factor: 17.298
2020 SCImago Journal Rankings: 5.488

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_US
dc.contributor.authorWong, Den_US
dc.contributor.authorSeto, Wen_US
dc.contributor.authorLai, Cen_US
dc.contributor.authorYuen, Men_US
dc.date.accessioned2014-07-07T08:14:45Z-
dc.date.available2014-07-07T08:14:45Z-
dc.date.issued2013en_US
dc.identifier.citationThe 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD: The Liver Meeting 2013), Washington, DC., 1-5 November 2013. In Hepatology, 2013, v. 58 n. S1, p. 634A, abstract no. 898en_US
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/198625-
dc.descriptionPoster - HBV Natural History and Outcomes: abstract no. 898-
dc.descriptionThis journal suppl. entitled: Special Issue: The 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013-
dc.description.abstractBACKGROUND: In chronic hepatitis B (CHB), the implications of hepatitis B e-antigen (HBeAg) seroconversion on subsequent hepatitis B surface antigen (HBsAg) seroclearance has not been documented. METHODS: The Chronic Hepatitis B E-Seroconversion Study (C.H.E.S.S.) cohort follows up a large population of CHB patients with documented HBeAg seroclearance. Patients are followed-up at 3-6 monthly intervals with routine liver biochemistry and viral serological tests. Results: A total of 803 patients with documented HBeAg seroconversion were included, with a median HBeAg seroconversion age of 34 years. The median follow-up length was 123 months after HBeAg seroclearance, with a total of 9250 patient-years. Of these, 502 (62.5%) were male. The cumulative rate of ...-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatologyen_US
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleSpontaneous hepatitis B e-antigen seroconversion without subsequent antiviral therapy is associated with higher rates of hepatitis B surface antigen seroclearanceen_US
dc.typeConference_Paperen_US
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailWong, D: danywong@hku.hken_US
dc.identifier.emailSeto, W: wkseto2@hku.hken_US
dc.identifier.emailLai, C: hrmelcl@hku.hken_US
dc.identifier.emailYuen, M: mfyuen@hku.hken_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityWong, D=rp00492en_US
dc.identifier.authoritySeto, W=rp01659en_US
dc.identifier.authorityLai, C=rp00314en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/hep.26727-
dc.identifier.hkuros229851en_US
dc.identifier.volume58-
dc.identifier.issueS1-
dc.identifier.spage634A-
dc.identifier.epage634A-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 140711-
dc.identifier.issnl0270-9139-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats